Live Breaking News & Updates on Armaceutiche|Page 3

Stay updated with breaking news from Armaceutiche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Menarini Industrie Farmaceutiche Riunite: QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC Platform

Agreement will initially cover the UK and France with potential to expand to other European countries and worldwideNEWCASTLE UPON TYNE, England and FLORENCE, Italy, Nov. 2, 2022 /PRNewswire/ ....

United Kingdom , Kostenloser Wertpapierhandel , Fabio Piazzalunga , Jonathan Ohalloran , Human Touch Of Technology , European Union , Prnewswire Quantumdx Group Limited , Menarini Pharmaceutical Group , Group Limited , United Kingdom Based , Chief Executive Officer , Global Head , Vitro Diagnostics Directive , Menarini Diagnostics , Human Touch ,

Menarini Industrie Farmaceutiche Riunite: Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis

NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and ....

United States , United Kingdom , Northern Ireland , South Korea , Reshma Rangwala , Selective Inhibitor Of Nuclear Export , Menarini Group , Committee For Orphan Medicinal Products , European Union , Head Of Medical Affairs Oncology , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Exchange Commission , Prnewswire Karyopharm Therapeutics Inc , National Organization Of Rare Diseases , European Medicines Agency , European Economic Area , Chief Medical Officer , Olivia Del Puerto , Medical Affairs Oncology , Orphan Medicinal , National Organization , Rare Diseases , Northern European , Product Characteristics ,

Menarini Industrie Farmaceutiche Riunite: Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- ....

United States , France General , Kostenloser Wertpapierhandel , Elcin Barker Ergun , Menarini Group , European Union , Drug Administration , Radius Health Inc , European Society For Medical Oncology , Stemline Therapeutics , Marketing Authorization Application , Chief Executive Officer , Clinical Oncology , European Society , Medical Oncology , Radius Health , Fast Track ,

Menarini Industrie Farmaceutiche Riunite: Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancerSubmission ....

New York , United States , Kostenloser Wertpapierhandel , Elcin Barker Ergun , Company New Drug Application , Menarini Group , Drug Administration , European Medicines Agency , Radius Health Inc , Menarini Group Logo , Prescription Drug User Fee Act , Stemline Therapeutics , New Drug Application , Priority Review , Fast Track , Chief Executive Officer , Marketing Authorization Application , Radius Health , New York City ,

Menarini Industrie Farmaceutiche Riunite: NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over €1 billion; including €142.5 million ....

United States , Noord Holland , Newamsterdam Pharma , Kostenloser Wertpapierhandel , Prnewswire Newamsterdam Pharma , Michael Davidson , Elcin Barker Ergun , John Kastelein , Lina Gugucheva , Covington Burling , Menarini Group , Goldman Sachs , Moelis Company , Amsterdam Pharma , Chief Executive Officer , Morningside Ventures ,